-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
450,450 Shares in Sunshine Biopharma, Inc. (NASDAQ:SBFM) Acquired by Empery Asset Management LP
450,450 Shares in Sunshine Biopharma, Inc. (NASDAQ:SBFM) Acquired by Empery Asset Management LP
Empery Asset Management LP purchased a new position in Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Rating) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 450,450 shares of the company's stock, valued at approximately $1,104,000. Sunshine Biopharma makes up about 5.2% of Empery Asset Management LP's investment portfolio, making the stock its 5th largest holding. Empery Asset Management LP owned 2.73% of Sunshine Biopharma as of its most recent SEC filing.
Sunshine Biopharma Price Performance
NASDAQ SBFM opened at $1.06 on Tuesday. The stock's 50 day moving average is $1.15 and its 200 day moving average is $1.99. Sunshine Biopharma, Inc. has a 12 month low of $1.01 and a 12 month high of $29.80.
Get Sunshine Biopharma alerts:About Sunshine Biopharma
(Get Rating)
Sunshine Biopharma, Inc, a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound.Further Reading
- Get a free copy of the StockNews.com research report on Sunshine Biopharma (SBFM)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
Want to see what other hedge funds are holding SBFM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Rating).
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
Empery Asset Management LP purchased a new position in Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Rating) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 450,450 shares of the company's stock, valued at approximately $1,104,000. Sunshine Biopharma makes up about 5.2% of Empery Asset Management LP's investment portfolio, making the stock its 5th largest holding. Empery Asset Management LP owned 2.73% of Sunshine Biopharma as of its most recent SEC filing.
根据向美国证券交易委员会提交的最新13F表格，Empery Asset Management LP在第一季度购买了阳光生物制药公司（纳斯达克股票代码：SBFM — 获取评级）的新头寸。该基金购买了该公司450,450股股票，价值约1,104,000美元。阳光生物制药约占Empery Asset Management LP投资组合的5.2％，使该股成为其第五大持股。截至向美国证券交易委员会提交最新文件，Empery Asset Management LP拥有阳光生物制药2.73％的股份。
Sunshine Biopharma Price Performance
阳光生物制药价格表现
NASDAQ SBFM opened at $1.06 on Tuesday. The stock's 50 day moving average is $1.15 and its 200 day moving average is $1.99. Sunshine Biopharma, Inc. has a 12 month low of $1.01 and a 12 month high of $29.80.
纳斯达克SBFM周二开盘报1.06美元。该股的50天移动平均线为1.15美元，其200天移动平均线为1.99美元。阳光生物制药公司的12个月低点为1.01美元，12个月高点为29.80美元。
About Sunshine Biopharma
关于阳光生物制药
(Get Rating)
（获取评级）
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Sunshine Biopharma (SBFM)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- 免费获取 StockNews.com 关于阳光生物制药（SBFM）的研究报告
- 这些股息成就者值得在你的投资组合中占有一席之地吗？
- Darden 餐厅走低路对抗通货膨胀
- 为什么这三只股票9月开盘火热
- 通货膨胀没有区别，但其影响确实如此
- 3只评级下调的必备股票
Want to see what other hedge funds are holding SBFM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Rating).
想看看还有哪些对冲基金持有SBFM吗？访问HoldingSchannel.com，获取阳光生物制药公司（纳斯达克股票代码：SBFM — 获取评级）的最新13F申报和内幕交易。
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收阳光生物制药日报的新闻和评级——在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收阳光生物制药及相关公司最新新闻的简明每日摘要和分析师的评级。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧